Research Article
Regulation of pre–B cell colony-enhancing factor by STAT-3–dependent interleukin-6 trans-signaling: Implications in the pathogenesis of rheumatoid arthritis
Mari A. Nowell,
Peter J. Richards,
Ceri A. Fielding,
Simona Ognjanovic, Nick Topley, Anwen S. Williams,
Gillian Bryant-Greenwood,
Simon A. Jones,
Corresponding Author
Mari A. Nowell
Cardiff University School of Medicine, Cardiff, UK
Medical Biochemistry and Immunology, Tenovus Building, School of Medicine, Heath Park Campus, Cardiff University, Cardiff CF14 4XN, UKSearch for more papers by this authorPeter J. Richards
Cardiff University School of Medicine, Cardiff, UK
Search for more papers by this authorCeri A. Fielding
Cardiff University School of Medicine, Cardiff, UK
Search for more papers by this authorAnwen S. Williams
Cardiff University School of Medicine, Cardiff, UK
Search for more papers by this authorGillian Bryant-Greenwood
John A. Burns School of Medicine, University of Hawaii, Honolulu
Search for more papers by this authorSimon A. Jones
Cardiff University School of Medicine, Cardiff, UK
Search for more papers by this authorMari A. Nowell,
Peter J. Richards,
Ceri A. Fielding,
Simona Ognjanovic, Nick Topley, Anwen S. Williams,
Gillian Bryant-Greenwood,
Simon A. Jones,
Corresponding Author
Mari A. Nowell
Cardiff University School of Medicine, Cardiff, UK
Medical Biochemistry and Immunology, Tenovus Building, School of Medicine, Heath Park Campus, Cardiff University, Cardiff CF14 4XN, UKSearch for more papers by this authorPeter J. Richards
Cardiff University School of Medicine, Cardiff, UK
Search for more papers by this authorCeri A. Fielding
Cardiff University School of Medicine, Cardiff, UK
Search for more papers by this authorAnwen S. Williams
Cardiff University School of Medicine, Cardiff, UK
Search for more papers by this authorGillian Bryant-Greenwood
John A. Burns School of Medicine, University of Hawaii, Honolulu
Search for more papers by this authorSimon A. Jones
Cardiff University School of Medicine, Cardiff, UK
Search for more papers by this authorAbstract
Objective
To determine whether interleukin-6 (IL-6) trans-signaling directs the expression of pre–B cell colony-enhancing factor (PBEF) in vitro and in vivo.
Methods
Complementary DNA from rheumatoid arthritis (RA) synovial fibroblasts treated with IL-6 and soluble IL-6 receptor (sIL-6R) was used to probe a cytokine microarray. PBEF regulation by the IL-6–related cytokines, IL-6, sIL-6R, oncostatin M (OSM), IL-11, and leukemia inhibitory factor (LIF) was determined by reverse transcription–polymerase chain reaction analysis. IL-6–mediated STAT-3 regulation of PBEF was determined using a cell-permeable STAT-3 inhibitor peptide. Antigen-induced arthritis (AIA) was induced in wild-type (IL-6+/+) and IL-6–deficient (IL-6−/−) mice. PBEF and STAT were detected by immunohistochemistry, immunoblotting, and electrophoretic mobility shift assay. Synovial levels of PBEF were quantified by enzyme immunoassay.
Results
IL-6 trans-signaling regulated PBEF in a STAT-3–dependent manner. In addition, PBEF was regulated by the IL-6–related cytokine OSM, but not IL-11 or LIF. Flow cytometric analysis of the IL-6–related cognate receptors suggested that OSM regulates PBEF via its OSM receptor β and not its LIF receptor. The involvement of PBEF in arthritis progression was confirmed in vivo, where induction of AIA resulted in a 4-fold increase in the synovial expression of PBEF. In contrast, little or no change was observed in IL-6−/− mice, in which the inflammatory infiltrate was markedly reduced and synovial STAT-1/3 activity was also impaired. Analysis of human RA synovial tissue confirmed that PBEF immunolocalized in apical synovial membrane cells, endothelial cells, adipocytes, and lymphoid aggregates. Synovial fluid levels of PBEF were significantly higher in RA patients than in osteoarthritis patients.
Conclusion
Experiments presented herein demonstrate that PBEF is regulated via IL-6 trans-signaling and the IL-6–related cytokine OSM. PBEF is also actively expressed during arthritis. Although these data confirm an involvement of PBEF in disease progression, the consequence of its action remains to be determined.
REFERENCES
- 1 Buckley CD, Pilling D, Lord JM, Akbar AN, Scheel-Toellner D, Salmon M. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation [review]. Trends Immunol 2001; 22: 199–204.
- 2 Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signaling through the gp130/Jak/STAT pathway [review]. Biochem J 1998; 334: 297–314.
- 3 Jones SA, Rose-John S. The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex [review]. Biochim Biophys Acta 2002; 1592: 251–63.
- 4 Nowell MA, Richards PJ, Horiuchi S, Yamamoto N, Rose-John S, Topley N, et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: Blockade of arthritis severity by soluble glycoprotein 130. J Immunol 2003; 171: 3202–9.
- 5 Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, et al. Toxicity, pharmacokinetics and dose-finding study of repetitive treatment with humanized anti-interleukin-6 receptor antibody MRA in rheumatoid arthritis. J Rheumatol 2003; 30: 1426–35.
- 6 Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human Pre-B-Cell Colony-Enhancing Factor. Mol Cell Biol 1994; 14: 1431–7.
- 7 Ognjanovic S, Bao S, Yamamoto SY, Garibay-Tupas J, Samal B, Bryant-Greenwood GD. Genomic organization of the gene coding for human pre-B-cell colony-enhancing factor and expression in human fetal membranes. J Mol Endocrinol 2001; 26: 107–17.
- 8 Ognjanovic S, Bryant-Greenwood GD. Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. Am J Obstet Gynecol 2002; 187: 1051–8.
- 9 Ye SQ, Simon BA, Maloney JP, Zambelli-Weiner A, Gao L, Grant A, et al. Pre-B-Cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med 2005; 171: 361–70.
- 10 Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, et al. Pre-B-cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004; 113: 1318–27.
- 11 Fukuhara A, Matsuda M, Nishizawa K, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426–30.
- 12 Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Hauri E, et al. Phosphotyrosyl peptides block stat3-mediated DNA binding activity, gene regulation and cell transformation. J Biol Chem 2001; 276: 45443–55.
- 13 Hufton SE, Moerkerk PT, Brandwijk R, de Bruine AP, Arends JW, Hoogenboom HR. A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization. FEBS Lett 1999; 463: 77–82.
- 14 Li FK, Davenport A, Robson R, Loetscher P, Rothlein R, Williams JD, et al. Leukocyte migration across human peritoneal mesothelial cells is dependent on directed chemokine secretion and ICAM-1 expression. Kidney Int 1998; 54: 2170–83.
- 15 McLoughlin RM, Hurst SM, Nowell MA, Harris DA, Horiuchi S, Morgan LW, et al. Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. J Immunol 2004; 172: 5676–83
- 16 Darnell JE. STATs and gene regulation [review]. Science 1997; 277: 1630–5.
- 17 Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 1761–9.
- 18 Richards PJ, Nowell MA, Horiuchi S, McLoughlin RM, Fielding CA, Grau S, et al. Functional characterization of a recombinant human soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis Rheum 2006; 54: 1662–72.
- 19 Shouda R, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest 2001; 108: 1781–8.
- 20 Shahara S, Amin MA, Woods JM, Haines GK, Koch AE. Chemokine receptor expression and in vivo signaling pathways in the joints of rats with adjuvant-induced arthritis. Arthritis Rheum 2003; 48: 3568–83.
- 21 Krause A, Scaletta N, Ji JD, Ivashkiv LB. Rheumatoid arthritis synoviocyte survival is dependent on STAT3. J Immunol 2002; 169: 6610–6
- 22 Atsumi T, Ishihara K, Kamimura D, Ikushima H, Ohtani T, Hirota S, et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med 2002; 196: 979–90.
- 23 Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001; 14: 705–14.
- 24 Manicourt DH, Poilvache P, Van Egeren A, Devogelaer JP, Lenz ME, Thonar EJ. Synovial fluid levels of tumor necrosis factor α and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. Arthritis Rheum 2000; 43: 281–8.
- 25 Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum 1997; 40: 1096–105.
- 26 Heinrich P, Behrmann I, Haan S, Hermanns H, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signaling and its regulation [review]. Biochem J 2003; 374: 1–20.
- 27 Gearing D, Bruce A. Oncostatin M binds the high-affinity leukemia inhibitory factor receptor. New Biol 1992; 4: 61–5.
- 28 Auguste P, Guillet C, Fourcin M, Olivier C, Veziers J, Pouplard-Barthelaix A, et al. Signaling of type II oncostatin M receptor. J Biol Chem 1997; 272: 15760–4.
- 29 Diveu C, Lak-Hal A, Froger J, Ravon E, Grimaud L, Barbier F, et al. Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling. Eur Cytokine Netw 2004; 15: 291–302.
- 30 Hermann JA, Hall MA, Maini RN, Feldmann M, Brennan FM. Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1388–97.
- 31 Moreland L, Gugliotti R, King K, Chase W, Weisman M, Greco T, et al. Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. Arthritis Res 2001; 3: 247–52.
- 32 Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gomez-Reino JJ, et al. Changes in fat-derived hormones plasma concentrations: adiponectin, leptin, resistin, and visfatin in rheumatoid arthritis subjects. Ann Rheum Dis 2006. E-pub ahead of print.
- 33 Pope R. Apoptosis as a therapeutic tool in rheumatoid arthritis [review]. Nat Rev Immunol 2002; 2: 527–35.
- 34 Ottonello L, Cutolo M, Frumento G, Arduino N, Bertolotto M, Mancini M, et al. Synovial fluid from patients with rheumatoid arthritis inhibits neutrophil apoptosis: role of adenosine and proinflammatory cytokines. Rheumatology 2002; 41: 1249–60.
- 35 Liu H, Pope R. The role of apoptosis in rheumatoid arthritis [review]. Curr Opin Pharmacol 2003; 3: 317–22.
- 36 Koch AE. Chemokines and their receptors in rheumatoid arthritis: future targets? [review]. Arthritis Rheum 2005; 52: 710–721.
- 37 Ognjanovic S, Ku T, Bryant-Greenwood G. Pre-B-cell colony-enhancing factor is a secreted cytokine-like protein from the human amniotic epithelium. Am J Obstet Gynecol 2005; 193: 273–282.
- 38 Xu LG, Wu M, Hu J, Zhai Z, Slu HB. Identification of downstream genes upregulated by the tumor necrosis factor family member TALL-1. J Leukoc Biol 2002; 72: 410–6.
- 39 Patrone L, Damore MA, Lee MB, Malone CS, Wall R. Genes expressed during the IFNγ-induced maturation of pre-B cells. Mol Immunol 2001; 38: 597–606.
- 40 Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocr Metab 2006; 91: 295–9.
- 41 Martin PR, Shea R, Mulks MH. Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence. J Bacteriol 2001; 183: 1168–74.
- 42
Rongvaux A,
Shea RJ,
Mulks MH,
Gigot D,
Urbain J,
Leo O, et al.
Pre-B-cell colony-enhancing factor, whose expression is upregulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis.
Eur J Immunol
2002;
32:
3225–34.
10.1002/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L CAS PubMed Web of Science® Google Scholar
- 43 Revollo JR, Grimm AA, Imai SI. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 2004; 279: 50754–63.
- 44 Sestini S, Jacomelli G, Pescaglini M, Micheli V, Popucci G. Enzyme activities leading to NAD synthesis in human lymphocytes. Arch Biochem Biophys 2000; 379: 277–82.
- 45 Hassman M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for the induction of tumor cell apoptosis. Cancer Res 2003; 63: 7436–42.
- 46 Holen KD, Burk K, Schwartz GK, Spriggs D, Hollywood E, Ty V, et al. Dose-finding and pharmacokinetic study of FK866, an inhibitor of NAD biosynthesis [abstract]. Proc Am Soc Clin Oncol 2002; 21: A346.
- 47 Chaput M, Claes V, Portetelle D, Cludts I, Cravador A, Burny A, et al. The neurotrophic factor neuroleukin is 90% homologous with phosphohexose isomerase. Nature 998; 332: 454–55.
- 48 Xu Q, Leiva MC, Fischkoff SA, Handschumacher RE, Lyttle CR. Leukocyte chemotactic activity of cyclophylin. J Biol Chem 1992; 267: 11968–71.
- 49 Hoogewerg AJ, Leone JW, Reardon IM, Howe AJ, Asa D, Heinrikson RL, et al. CXC chemokines connective tissue activation peptide-III and Neutrophil activating peptide-2 are heparin/heparan sulfate-degrading enzymes. J Biol Chem 1995; 270: 3268–77.
- 50 Swope M, Sun H, Blake PR, Lolis E. Direct link between cytokine activity and a catalytic site for macrophage migration inhibitory factor. EMBO J 1998; 17: 3534–41.
- 51 Calandra T, Roger T. Macrophage Migration Inhibitory Factor: A regulator of innate immunity [review]. Nat Rev Immunol 2003; 3: 791–800.
- 52 Kitani T, Okuno S, Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett 2003; 544: 74–8.
- 53 Pyle M, Korbonits M, Guerorguiev M, Jordan S, Kola B, Morris D, et al. Macrophage migration inhibitory factor expression is increased in pituitary adenoma cell nuclei. J Endocrinol 2003; 176: 103–10.
- 54 Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, et al. MIF signal transduction initiated by binding to CD74. J Exp Med 2003; 197: 1467–76.
